Sinotherapeutics (SH:688247)2025-02-26 07:50Financial Performance - The total operating revenue for 2024 reached CNY 51,269.10 million, representing a year-on-year increase of 70.97%[3] - The net profit attributable to the parent company was CNY 12,823.46 million, up 109.97% compared to the previous year[5] - The net profit attributable to the parent company after deducting non-recurring gains and losses increased by 140.89% to CNY 11,435.84 million[6] - Basic earnings per share rose to CNY 0.28, reflecting a 115.38% increase year-on-year[6] Asset and Equity Growth - The total assets at the end of the reporting period were CNY 145,408.05 million, a growth of 6.79% from the beginning of the period[5] - The equity attributable to the parent company increased by 5.16% to CNY 127,269.58 million[5] - The weighted average return on net assets improved by 5.28 percentage points to 10.42%[6] Revenue Drivers - Significant revenue growth was driven by the successful listing of products in various markets, including the U.S. for Mesalazine enteric-coated tablets[6] - CMO revenue saw a notable increase due to the commercialization of client products[5] Financial Data Disclaimer - The company emphasizes the preliminary nature of the financial data, which is subject to final audit adjustments[8]